John Hartley

John Hartley is Professor of Cancer Studies in the UCL Cancer Institute and Co-Lead of the UCL Experimental Cancer Medicine Centre. He is also Director of the Cancer Research UK Drug-DNA Interactions Research Group. His research activities are focused around the development of novel cancer therapies, particularly involving DNA as a target.

He obtained a first degree in Biochemistry and a PhD in Oncology, both from Manchester University, and undertook post-doctoral studies at the National Cancer Institute, NIH, USA and the University of Alberta in Canada. He has been at UCL for over 20 years and is a founder of spin-out company Spirogen which was acquired by AstraZeneca in 2013. He continues to be involved at Spirogen as Director of Pre-Clinical Development.